|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Then we subgroup the patients with GFR ≥ 90 mg/min/1.73 m<sup>2</sup>, to exclude the effects of lower renal function on cystatin C. No statistically significant differences in the levels of serum Cys-C were found among the tumor characteristics (all <i>P</i> > 0.05).
|
29789781 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The present study was performed to evaluate the efficacy of circulating cystatin-C as a tumor monitoring biomarker at different clinical time points in patients with breast cancer over a long-term follow-up period.
|
30344712 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This decrease in cystatin C concentrations was correlated with cathepsin D (r = 0.307; P < 0.001), which was released from the tumour during targeted therapy.
|
28482048 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Utility of cystatin C as a potential bladder tumour biomarker confirmed by surface plasmon resonance technique.
|
29749360 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, cystatin C over-expression significantly decreased tumor invasiveness (P<0.05) while the invasiveness of EC9706 cells was significantly enhanced by RNAi-mediated abrogation of cystatin C gene expression (P<0.05).
|
26617717 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cathepsin D secreted by breast cancer cells also processed cystatin C at the pericellular pH of tumors and so enhancing extracellular proteolytic activity of cysteine cathepsins.
|
22898924 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The intensity of cystatin C immunostaining in tumor tissues was increased compared to that of adjacent normal tissues. mRNA expression of the cystatin C gene was greater in esophageal cancer than in normal tissues (P <0.05).
|
21617716 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the clinical samples of meningioma, the levels of cathepsins B and L, stefin B, and cystatin C were highest in the tumors of higher histological grades, whereas stefin A and progesterone receptor were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions.
|
19747051 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although mitogenic vascular endothelial growth factor, transforming growth factor-beta1, and the anti-angiogenic endostatin levels in either serum or carcinoma tissue extracts did not change in cathepsin S- or cystatin C-null mice, tumor tissue basic fibroblast growth factor and serum type 1 insulin growth factor levels were higher in cystatin C-null mice, and serum type 1 insulin growth factor levels were also increased in cathepsin S-null mice.
|
16365041 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In univariate analysis, the patients with low tumour cystatin C levels exhibited poor disease-free survival (DFS, P=0.013) and disease-specific survival (DSS, P=0.013).
|
15138478 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed progressive reductions in levels of the protease inhibitor cystatin C, an inhibitor of cathepsin B with corresponding increases in the malignancy of glioma cell lines, implying an inverse correlation between cystatin C and tumor grade.
|
12483523 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results, however, clearly indicate that neither transthyretin nor cystatin C constitutes a useful marker for such neoplasms.
|
7665147 |
1995 |